Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 3,923 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 3,923 shares of SiBone stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $20.02, for a total transaction of $78,538.46. Following the completion of the sale, the chief executive officer directly owned 317,463 shares in the company, valued at $6,355,609.26. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Stock Performance

Shares of SIBN stock traded up $0.48 on Friday, hitting $19.96. 1,290,316 shares of the stock were exchanged, compared to its average volume of 620,561. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $885.21 million, a PE ratio of -58.71 and a beta of 0.66. SiBone has a one year low of $11.48 and a one year high of $21.89. The firm’s 50 day moving average is $17.40 and its two-hundred day moving average is $15.30.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Sell-side analysts expect that SiBone will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. First Light Asset Management LLC boosted its holdings in SiBone by 6.4% in the 1st quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after purchasing an additional 320,286 shares during the period. Vanguard Group Inc. raised its position in shares of SiBone by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock worth $49,331,000 after buying an additional 11,566 shares in the last quarter. Granahan Investment Management LLC boosted its stake in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after buying an additional 858,942 shares during the period. Nuveen LLC boosted its stake in SiBone by 5.1% during the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after buying an additional 69,229 shares during the period. Finally, Impax Asset Management Group plc grew its position in SiBone by 17.1% during the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock worth $23,664,000 after buying an additional 175,000 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

Analyst Ratings Changes

SIBN has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Truist Financial reiterated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. UBS Group boosted their target price on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, TD Cowen increased their target price on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.17.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.